Tuberculosis (TB) is a highly complex and variable disease that presents along a spectrum of infection outcomes.
The TB granuloma is a primary contributor to the biological heterogeneity of TB.
Local inflammation, the immune response and bacterial state all contribute to the outcome of a granuloma, and thus there are multiple pathways by which to either achieve control or promote dissemination.
The failure of one or a few granulomas is sufficient to initiate disease progression and influence the clinical status of the host.
Infection with Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), results in a range of clinical presentations in humans. Most infections manifest as a clinically asymptomatic, contained state that is termed latent TB infection (LTBI); a smaller subset of infected individuals present with symptomatic, active TB. Within these two seemingly binary states, there is a spectrum of host outcomes that have varying symptoms, microbiologies, immune responses and pathologies. Recently, it has become apparent that there is diversity of infection even within a single individual. A good understanding of the heterogeneity that is intrinsic to TB — at both the population level and the individual level — is crucial to inform the development of intervention strategies that account for and target the unique, complex and independent nature of the local host–pathogen interactions that occur in this infection. In this Review, we draw on model systems and human data to discuss multiple facets of TB biology and their relationship to the overall heterogeneity observed in the human disease.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
A clinical indicator-based prognostic model predicting treatment outcomes of pulmonary tuberculosis: a prospective cohort study
BMC Infectious Diseases Open Access 20 February 2023
Plasma cytokine levels characterize disease pathogenesis and treatment response in tuberculosis patients
Infection Open Access 27 June 2022
Scientific Reports Open Access 16 June 2022
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Getahun, H., Matteelli, A., Chaisson, R. E. & Raviglione, M. Latent Mycobacterium tuberculosis infection. N. Engl. J. Med. 372, 2127–2135 (2015).
Corbett, E. L. et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163, 1009–1021 (2003).
Lawn, S. D. & Zumla, A. I. Tuberculosis. Lancet 378, 57–72 (2011).
World Health Organization. Global Tuberculosis Report 2015 (World Health Organization, 2015).
Andrews, J. R. et al. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin. Infect. Dis. 54, 784–791 (2012).
Lin, P. L. & Flynn, J. L. Understanding latent tuberculosis: a moving target. J. Immunol. 185, 15–22 (2010).
Chen, R. Y. et al. PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Sci. Transl Med. 6, 265ra166 (2014).
Lenzini, L., Rottoli, P. & Rottoli, L. The spectrum of human tuberculosis. Clin. Exp. Immunol. 27, 230–237 (1977).
Poulsen, A. Some clinical features of tuberculosis. Acta Tuberc. Scand. 33, 37–92 (1957).
Barry, C. E. 3rd et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7, 845–855 (2009).
Young, D. B., Gideon, H. P. & Wilkinson, R. J. Eliminating latent tuberculosis. Trends Microbiol. 17, 183–188 (2009).
Esmail, H. et al. Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography. Nat. Med. 22, 1090–1093 (2016). This study provides evidence of subclinical, active disease in a subset of adults infected with HIV-1 and latent TB, reiterating the spectrum of disease seen in human TB.
Capuano, S. V. et al. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect. Immun. 71, 5831–5844 (2003).
Lin, P. L. et al. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect. Immun. 77, 4631–4642 (2009).
Berry, M. P. et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466, 973–977 (2010). Using transcriptional profiling of whole blood, this study identifies a discriminatory, IFN-inducible, neutrophil-mediated signature of active TB. This work also provides new insights into the spectrum of TB by revealing a subset of patients with latent TB who have signatures that overlap closely with the signature of active disease.
Maertzdorf, J. et al. Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis. PLoS ONE 6, e26938 (2011).
Ottenhoff, T. H. et al. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS ONE 7, e45839 (2012).
Cliff, J. M., Kaufmann, S. H., McShane, H., van Helden, P. & O'Garra, A. The human immune response to tuberculosis and its treatment: a view from the blood. Immunol. Rev. 264, 88–102 (2015).
Bloom, C. I. et al. Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS ONE 7, e46191 (2012).
Cliff, J. M. et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J. Infect. Dis. 207, 18–29 (2013).
Zumla, A., Nahid, P. & Cole, S. T. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 12, 388–404 (2013).
Koul, A., Arnoult, E., Lounis, N., Guillemont, J. & Andries, K. The challenge of new drug discovery for tuberculosis. Nature 469, 483–490 (2011).
Blankley, S. et al. The transcriptional signature of active tuberculosis reflects symptom status in extra-pulmonary and pulmonary tuberculosis. PLoS ONE 11, e0162220 (2016).
Banchereau, R. et al. Host immune transcriptional profiles reflect the variability in clinical disease manifestations in patients with Staphylococcus aureus infections. PLoS ONE 7, e34390 (2012).
Zak, D. E. et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet 387, 2312–2322 (2016).
Mehra, S. et al. Transcriptional reprogramming in nonhuman primate (rhesus macaque) tuberculosis granulomas. PLoS ONE 5, e12266 (2010).
Gideon, H. P., Skinner, J. A., Baldwin, N., Flynn, J. L. & Lin, P. L. Early whole blood transcriptional signatures are associated with severity of lung inflammation in cynomolgus macaques with Mycobacterium tuberculosis infection. J. Immunol. 197, 4817–4828 (2016).
Williams, G. T. & Williams, W. J. Granulomatous inflammation — a review. J. Clin. Pathol. 36, 723–733 (1983).
Russell, D. G., Cardona, P. J., Kim, M. J., Allain, S. & Altare, F. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat. Immunol. 10, 943–948 (2009).
Flynn, J. L., Chan, J. & Lin, P. L. Macrophages and control of granulomatous inflammation in tuberculosis. Mucosal Immunol. 4, 271–278 (2011).
Davis, J. M. & Ramakrishnan, L. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 136, 37–49 (2009).
Ramakrishnan, L. Revisiting the role of the granuloma in tuberculosis. Nat. Rev. Immunol. 12, 352–366 (2012).
Flynn, J. L. Mutual attraction: does it benefit the host or the bug? Nat. Immunol. 5, 778–779 (2004).
O'Garra, A. et al. The immune response in tuberculosis. Annu. Rev. Immunol. 31, 475–527 (2013).
Canetti, G. The Tubercle Bacillus in the Pulmonary Lesion of Man; Histobacteriology and its Bearing on the Therapy of Pulmonary Tuberculosis (Springer, 1955).
Ford, C. B. et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat. Genet. 43, 482–486 (2011).
Lin, P. L. et al. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat. Med. 20, 75–79 (2014). This study is the first to demonstrate that the majority of granulomas are seeded by a single bacillus and that there is differential bacterial killing of granulomas within the host that is independent of host status. These findings shift the focus to the local granuloma level and suggest that the individual trajectories of granulomas influence the clinical outcome of infection.
Subbian, S. et al. Lesion-specific immune response in granulomas of patients with pulmonary tuberculosis: a pilot study. PLoS ONE 10, e0132249 (2015).
Lenaerts, A., Barry, C. E. III & Dartois, V. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol. Rev. 264, 288–307 (2015).
Coleman, M. T. et al. Early changes by 18fluorodeoxyglucose positron emission tomography coregistered with computed tomography predict outcome after Mycobacterium tuberculosis infection in cynomolgus macaques. Infect. Immun. 82, 2400–2404 (2014). This study reveals that early granuloma dissemination and inflammation influence the clinical outcome of infection in infected cynomolgus macaques.
Cadena, A. M., Flynn, J. L. & Fortune, S. M. The importance of first impressions: early events in Mycobacterium tuberculosis infection influence outcome. mBio 7, e00342-16 (2016).
Lieberman, T. D. et al. Genomic diversity in autopsy samples reveals within-host dissemination of HIV-associated Mycobacterium tuberculosis. Nat. Med. 22, 1470–1474 (2016).
Cooper, A. M., Mayer-Barber, K. D. & Sher, A. Role of innate cytokines in mycobacterial infection. Mucosal Immunol. 4, 252–260 (2011).
Lerner, T. R., Borel, S. & Gutierrez, M. G. The innate immune response in human tuberculosis. Cell. Microbiol. 17, 1277–1285 (2015).
Lin, P. L. et al. Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. Infect. Immun. 74, 3790–3803 (2006).
Marakalala, M. J. et al. Inflammatory signaling in human tuberculosis granulomas is spatially organized. Nat. Med. 22, 531–538 (2016). By analysing the proteomes of human and rabbit granulomas, this study reveals that pro-inflammatory and anti-inflammatory programmes occur simultaneously, but in physically distinct compartments.
Fallahi-Sichani, M., El-Kebir, M., Marino, S., Kirschner, D. E. & Linderman, J. J. Multiscale computational modeling reveals a critical role for TNF-α receptor 1 dynamics in tuberculosis granuloma formation. J. Immunol. 186, 3472–3483 (2011).
Guirado, E. & Schlesinger, L. S. Modeling the Mycobacterium tuberculosis granuloma — the critical battlefield in host immunity and disease. Front. Immunol. 4, 98 (2013).
Kaplan, G. et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect. Immun. 71, 7099–7108 (2003).
Ernst, J. D. The immunological life cycle of tuberculosis. Nat. Rev. Immunol. 12, 581–591 (2012).
Lin, P. L. et al. PET CT identifies reactivation risk in cynomolgus macaques with latent M. tuberculosis. PLoS Pathog. 12, e1005739 (2016).
Malherbe, S. T. et al. Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nat. Med. 22, 1094–1100 (2016). The authors of this paper show that in spite of a standard curative 6-month regimen, there were multiple patients with persistent pulmonary inflammation that was coincident with the detection of M. tuberculosis mRNA. These observations highlight the variability of treatment outcome in individual granulomas, even after a year of successful treatment, and implicate a complementary, ongoing requirement for immunity in maintaining sterility.
Mattila, J. T. et al. Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J. Immunol. 191, 773–784 (2013).
Tobin, D. M. et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 148, 434–446 (2012).
Chen, M. et al. Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J. Exp. Med. 205, 2791–2801 (2008).
Divangahi, M. et al. Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. Nat. Immunol. 10, 899–906 (2009).
Divangahi, M., Desjardins, D., Nunes-Alves, C., Remold, H. G. & Behar, S. M. Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat. Immunol. 11, 751–758 (2010).
Divangahi, M., Behar, S. M. & Remold, H. Dying to live: how the death modality of the infected macrophage affects immunity to tuberculosis. Adv. Exp. Med. Biol. 783, 103–120 (2013).
Mayer-Barber, K. D. et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511, 99–103 (2014). This study establishes a link between IL-1 and type I IFNs that is mediated by eicosanoids. It also confirms the role of host-directed manipulation of the eicosanoid balance in favour of prostaglandin E 2 in resolving disease exacerbations in vivo.
Wallis, R. S. & Hafner, R. Advancing host-directed therapy for tuberculosis. Nat. Rev. Immunol. 15, 255–263 (2015).
Orme, I. M., Robinson, R. T. & Cooper, A. M. The balance between protective and pathogenic immune responses in the TB-infected lung. Nat. Immunol. 16, 57–63 (2015).
Gideon, H. P. et al. Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization. PLoS Pathog. 11, e1004603 (2015).
Cilfone, N. A., Perry, C. R., Kirschner, D. E. & Linderman, J. J. Multi-scale modeling predicts a balance of tumor necrosis factor-α and interleukin-10 controls the granuloma environment during Mycobacterium tuberculosis infection. PLoS ONE 8, e68680 (2013).
Cilfone, N. A. et al. Computational modeling predicts IL-10 control of lesion sterilization by balancing early host immunity-mediated antimicrobial responses with caseation during Mycobacterium tuberculosis infection. J. Immunol. 194, 664–677 (2015).
Srivastava, S., Ernst, J. D. & Desvignes, L. Beyond macrophages: the diversity of mononuclear cells in tuberculosis. Immunol. Rev. 262, 179–192 (2014).
Behar, S. M., Carpenter, S. M., Booty, M. G., Barber, D. L. & Jayaraman, P. Orchestration of pulmonary T cell immunity during Mycobacterium tuberculosis infection: immunity interruptus. Semin. Immunol. 26, 559–577 (2014).
Guirado, E., Schlesinger, L. S. & Kaplan, G. Macrophages in tuberculosis: friend or foe. Semin. Immunopathol. 35, 563–583 (2013).
Sia, J. K., Georgieva, M. & Rengarajan, J. Innate immune defenses in human tuberculosis: an overview of the interactions between Mycobacterium tuberculosis and innate immune cells. J. Immunol. Res. 2015, 747543 (2015).
Martin, C. J. et al. Digitally barcoding Mycobacterium tuberculosis reveals in vivo infection dynamics in the macaque model of tuberculosis. mBio 8, e00312-17 (2017).
Cronan, M. R. et al. Macrophage epithelial reprogramming underlies mycobacterial granuloma formation and promotes infection. Immunity 45, 861–876 (2016).
Keane, J. et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. 345, 1098–1104 (2001).
Bruns, H. et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J. Clin. Invest. 119, 1167–1177 (2009).
Maini, R. et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354, 1932–1939 (1999).
Lin, P. L. et al. Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum. 62, 340–350 (2010).
Marino, S. et al. Computational and empirical studies predict Mycobacterium tuberculosis-specific T cells as a biomarker for infection outcome. PLoS Comput. Biol. 12, e1004804 (2016).
Marino, S. et al. Macrophage polarization drives granuloma outcome during Mycobacterium tuberculosis infection. Infect. Immun. 83, 324–338 (2015).
Kirschner, D. E. & Linderman, J. J. Mathematical and computational approaches can complement experimental studies of host–pathogen interactions. Cell. Microbiol. 11, 531–539 (2009).
Kirschner, D. E., Hunt, C. A., Marino, S., Fallahi-Sichani, M. & Linderman, J. J. Tuneable resolution as a systems biology approach for multi-scale, multi-compartment computational models. Wiley Interdiscip. Rev. Syst. Biol. Med. 6, 289–309 (2014).
Lopez, B. et al. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin. Exp. Immunol. 133, 30–37 (2003).
Ribeiro, S. C. et al. Mycobacterium tuberculosis strains of the modern sublineage of the Beijing family are more likely to display increased virulence than strains of the ancient sublineage. J. Clin. Microbiol. 52, 2615–2624 (2014).
Reed, M. B. et al. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 431, 84–87 (2004).
Dormans, J. et al. Correlation of virulence, lung pathology, bacterial load and delayed type hypersensitivity responses after infection with different Mycobacterium tuberculosis genotypes in a BALB/c mouse model. Clin. Exp. Immunol. 137, 460–468 (2004).
Manca, C. et al. Differential monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis. Infect. Immun. 72, 5511–5514 (2004).
Portevin, D., Gagneux, S., Comas, I. & Young, D. Human macrophage responses to clinical isolates from the Mycobacterium tuberculosis complex discriminate between ancient and modern lineages. PLoS Pathog. 7, e1001307 (2011).
Carmona, J. et al. Mycobacterium tuberculosis strains are differentially recognized by TLRs with an impact on the immune response. PLoS ONE 8, e67277 (2013).
Grant, A. J. et al. Modelling within-host spatiotemporal dynamics of invasive bacterial disease. PLoS Biol. 6, e74 (2008).
Joseph, S. B., Swanstrom, R., Kashuba, A. D. & Cohen, M. S. Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. Nat. Rev. Microbiol. 13, 414–425 (2015).
Jacobs, A. L. Infective dose in pulmonary tuberculosis. Tubercle 22, 266–271 (1941).
Walker, T. M. et al. Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect. Dis. 13, 137–146 (2013).
Bryant, J. M. et al. Inferring patient to patient transmission of Mycobacterium tuberculosis from whole genome sequencing data. BMC Infect. Dis. 13, 110 (2013).
Bigger, J. W. Treatment of staphylococcal infections with penicillin by intermittent sterilisation. Lancet 244, 497–500 (1944).
Kester, J. C. & Fortune, S. M. Persisters and beyond: mechanisms of phenotypic drug resistance and drug tolerance in bacteria. Crit. Rev. Biochem. Mol. Biol. 49, 91–101 (2014).
Mitchison, D. A. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int. J. Tuberc. Lung Dis. 2, 10–15 (1998).
Kieser, K. J. & Rubin, E. J. How sisters grow apart: mycobacterial growth and division. Nat. Rev. Microbiol. 12, 550–562 (2014).
Wakamoto, Y. et al. Dynamic persistence of antibiotic-stressed mycobacteria. Science 339, 91–95 (2013).
Fox, W., Ellard, G. A. & Mitchison, D. A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int. J. Tuberc. Lung Dis. 3, S231–S279 (1999).
Medlar, E. M., Bernstein, S. & Steward, D. M. A bacteriologic study of resected tuberculous lesions. Am. Rev. Tuberc. 66, 36–43 (1952).
Beck, F. & Yegian, D. A study of the tubercle bacillus in resected pulmonary lesions. Am. Rev. Tuberc. 66, 44–51 (1952).
Canetti, G. Anatomical and bacteriological changes in tuberculous lesions under the influence of antibiotics and chemotherapy. Bull. Int. Union Tuberc. 24, 144–240 (1954).
Salkin, D. & Wayne, L. G. The bacteriology of resected tuberculous pulmonary lesions. I. The effect of interval between reversal of infectiousness and subsequent surgery. Am. Rev. Tuberc. 74, 376–387 (1956).
Wayne, L. G. & Sohaskey, C. D. Nonreplicating persistence of Mycobacterium tuberculosis. Annu. Rev. Microbiol. 55, 139–163 (2001).
Vilcheze, C. & Kremer, L. Acid-fast positive and acid-fast negative Mycobacterium tuberculosis: the Koch paradox. Microbiol. Spectr. http://dx.doi.org/10.1128/microbiolspec.TBTB2-0003-2015 (2017).
Seiler, P. et al. Cell-wall alterations as an attribute of Mycobacterium tuberculosis in latent infection. J. Infect. Dis. 188, 1326–1331 (2003).
Obregon-Henao, A. et al. Cortisone-forced reactivation of weakly acid fast positive Mycobacterium tuberculosis in guinea pigs previously treated with chemotherapy. Mycobact. Dis. 2, 1000116 (2012).
Mukamolova, G. V., Turapov, O., Malkin, J., Woltmann, G. & Barer, M. R. Resuscitation-promoting factors reveal an occult population of tubercle bacilli in sputum. Am. J. Respir. Crit. Care Med. 181, 174–180 (2010).
Chengalroyen, M. D. et al. Detection and quantification of differentially culturable tubercle bacteria in sputum from patients with tuberculosis. Am. J. Respir. Crit. Care Med. 194, 1532–1540 (2016).
Garton, N. J. et al. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med. 5, e75 (2008).
Walter, N. D. et al. Transcriptional adaptation of drug-tolerant Mycobacterium tuberculosis during treatment of human tuberculosis. J. Infect. Dis. 212, 990–998 (2015).
Honeyborne, I. et al. Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy. BMC Med. 14, 68 (2016).
Sukumar, N., Tan, S., Aldridge, B. B. & Russell, D. G. Exploitation of Mycobacterium tuberculosis reporter strains to probe the impact of vaccination at sites of infection. PLoS Pathog. 10, e1004394 (2014).
Manina, G., Dhar, N. & McKinney, J. D. Stress and host immunity amplify Mycobacterium tuberculosis phenotypic heterogeneity and induce nongrowing metabolically active forms. Cell Host Microbe 17, 32–46 (2015).
Gillespie, S. H. et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N. Engl. J. Med. 371, 1577–1587 (2014).
Mukherjee, T. & Boshoff, H. Nitroimidazoles for the treatment of TB: past, present and future. Future Med. Chem. 3, 1427–1454 (2011).
Matsumoto, M. et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3, e466 (2006).
Stover, C. K. et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405, 962–966 (2000).
Koul, A. et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 3, 323–324 (2007).
Cole, S. T. Inhibiting Mycobacterium tuberculosis within and without. Phil. Trans. R. Soc. B Biol. Sci. http://dx.doi.org/10.1098/rstb.2015.0506 (2016).
Zhang, Y. & Mitchison, D. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. 7, 6–21 (2003).
Prideaux, B. et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat. Med. 21, 1223–1227 (2015). This study reveals that different drugs demonstrate variable penetration, accumulation and spatial distribution within tuberculous granulomas, thus setting up separate niches for the development of drug resistance and bacterial persistence.
Myllymaki, H., Bauerlein, C. A. & Ramet, M. The zebrafish breathes new life into the study of tuberculosis. Front. Immunol. 7, 196 (2016).
Kramnik, I. & Beamer, G. Mouse models of human TB pathology: roles in the analysis of necrosis and the development of host-directed therapies. Semin. Immunopathol. 38, 221–237 (2016).
Scanga, C. A. & Flynn, J. L. Modeling tuberculosis in nonhuman primates. Cold Spring Harb. Perspect. Med. 4, a018564 (2014).
Flynn, J. L., Gideon, H. P., Mattila, J. T. & Lin, P. L. Immunology studies in non-human primate models of tuberculosis. Immunol. Rev. 264, 60–73 (2015).
Pena, J. C. & Ho, W. Z. Monkey models of tuberculosis: lessons learned. Infect. Immun. 83, 852–862 (2015).
Diedrich, C. R. et al. Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS ONE 5, e9611 (2010).
Lin, P. L. et al. CD4 T cell depletion exacerbates acute Mycobacterium tuberculosis while reactivation of latent infection is dependent on severity of tissue depletion in cynomolgus macaques. AIDS Res. Hum. Retroviruses 28, 1693–1702 (2012).
Shah, J. A. et al. Human TOLLIP regulates TLR2 and TLR4 signaling and its polymorphisms are associated with susceptibility to tuberculosis. J. Immunol. 189, 1737–1746 (2012).
Shah, J. A. et al. A functional TOLLIP variant is associated with BCG-specific immune responses and tuberculosis. Am. J. Respir. Crit. Care Med. http://dx.doi.org/10.1164/rccm.201611-2346OC (2017).
Graustein, A. D. et al. The SIGLEC14 null allele is associated with Mycobacterium tuberculosis- and BCG-induced clinical and immunologic outcomes. Tuberculosis (Edinb.) 104, 38–45 (2017).
Smith, C. M. et al. Tuberculosis susceptibility and vaccine protection are independently controlled by host genotype. mBio 7, e01516-16 (2016).
Berrington, W. R. & Hawn, T. R. Mycobacterium tuberculosis, macrophages, and the innate immune response: does common variation matter? Immunol. Rev. 219, 167–186 (2007).
Casanova, J. L. & Abel, L. Genetic dissection of immunity to mycobacteria: the human model. Annu. Rev. Immunol. 20, 581–620 (2002).
Misch, E. A. & Hawn, T. R. Toll-like receptor polymorphisms and susceptibility to human disease. Clin. Sci. (Lond.) 114, 347–360 (2008).
Churchill, G. A. et al. The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat. Genet. 36, 1133–1137 (2004).
Collaborative Cross Consortium. The genome architecture of the Collaborative Cross mouse genetic reference population. Genetics 190, 389–401 (2012).
The authors gratefully acknowledge the intellectual contributions of the members of the Flynn and Fortune laboratories, as well as P. Ling Lin, E. Klein, J. Mattila and C. Scanga for helpful discussions. This work was supported, in part, by the US National Institutes of Health (T32 AI089443 to A.M.C.; AI094745, HL110811, AI105422 and AI123093 to J.L.F.; and AI114674 to J.L.F. and S.M.F.), the Bill and Melinda Gates Foundation (to J.L.F. and S.M.F.) and the Aeras Global Fund (to J.L.F. and S.M.F.). Support was also provided by the Burroughs Wellcome Foundation (to S.M.F.).
The authors declare no competing financial interests.
- Tuberculin skin test
A test that involves the induction of a delayed-type hypersensitivity reaction by an intradermal injection of purified protein derivative, which is a mixture of Mycobacterium tuberculosis-derived proteins. The tuberculin skin test is also known as the Mantoux test and is used as a diagnostic tool for M. tuberculosis infection, but it does not distinguish latent infection from active tuberculosis.
- Acid-fast staining
A method for staining mycobacteria for microscopic visualization, as the Gram stain is not useful for mycobacteria. Acid-fast staining relies on phenolic compounds that interact with the lipid-rich cell walls of mycobacteria, and the resistance of this interaction to acid alcohol is the basis of the term 'acid-fast'.
- Positron emission tomography
An imaging method that depends on the 3D detection of radiation (positrons) from a probe that is typically localized by uptake and retention in a specific cell or by a specific process in vivo. This uptake provides functional information about the organ of interest.
- Computed tomography
An imaging method that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional (tomographic) images (virtual 'slices') of specific areas of a scanned object, resulting in a 3D representation of an organ in a living subject. This provides structural information about the organ of interest.
- Pulmonary cavitation
The formation of a cavity in the lung. A cavity is an abnormal, gas-filled space with a lining wall that has developed within and replaced the normal lung architecture. In tuberculous disease, these cavities are formed when necrosis invades through the wall of an airway, dilating and distorting the structure, and leading to the discharge of necrotic debris into the bronchial tree.
- Ghon complex
A term for pathological lesions in latent tuberculosis infection that consist of an often-calcified granuloma and an associated lymph node.
- Molecular distance to health
A numerical score that measures the global transcriptional difference of each patient relative to the median in healthy controls.
A hallmark feature of human tuberculous granulomas that results from a distinctive type of central necrotic breakdown known as caseous necrosis. The term caseum derives from the 'cheese-like' appearance of the necrotic area.
Pathological processes by which the pulmonary infiltration of cells, fluid or other material leads to the loss of aeration and of the normal spongy consistency, causing parenchymal tissue to have a more firm, solid texture. Such a change is most commonly associated with infection-induced inflammatory infiltrates and leads to pneumonia.
About this article
Cite this article
Cadena, A., Fortune, S. & Flynn, J. Heterogeneity in tuberculosis. Nat Rev Immunol 17, 691–702 (2017). https://doi.org/10.1038/nri.2017.69
This article is cited by
A clinical indicator-based prognostic model predicting treatment outcomes of pulmonary tuberculosis: a prospective cohort study
BMC Infectious Diseases (2023)
Plasma cytokine levels characterize disease pathogenesis and treatment response in tuberculosis patients
Nature Reviews Microbiology (2022)
Scientific Reports (2022)
Nature Reviews Microbiology (2022)